Osteoporosis develops as a result of imbalance between bone resorption and bone formation. A number of effective and safe therapies for osteoporosis are currently available, most of which are inhibitors of bone resorption. However, because osteoporosis is a complex and heterogeneous disease with different pathogenetic factors, defining the role of the different factors in its development is important in formulating a more selective approach to therapy. This review discusses the advantages and disadvantages of the currently available agents used in the management of osteoporosis.
NIH Consensus Conference, “Osteoporosis, diagnosis and therapy.”JAMA2001;285:785–95.
2.
NordinBEC.Should the treatment of osteoporosis be more selective?Osteoporos Int2003;14:99–102.
3.
FrancisRM, SutcliffeAM, ScaneAC.Pathogenesis of osteoporosis. In:StevensonJC,LindsayR, editors. OsteoporosisLondon:Chapman and Hall; 1998:29–51.
4.
LipsP, CourponP, MeunierPJ.Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res1978;26:13–7.
5.
RiggsBL, MeltonLJ.Involutional osteoporosis. N Engl J Med1986;314:1676–86.
6.
MeltonLJIII,ChaoEYS, LaneJ.Biomechanical aspects of fractures. In:RiggsBL,MeltonLJIII, editors. Osteoporosis : etiology, diagnosis and management. New York: Raven Press; 1991:111–31.
7.
CummingsSR, BrownerW,CummingsSR, .Bone density at various sites for prediction of hip fractures. Lancet1993;341:72–5.
8.
CummingsSR, NevittMC, BrownerWS, StoneK, . Risk factors for hip fracture in white women. N Engl J Med1995;332:767–73.
9.
MillerPD, SirisES, Barrett-ConnorE, FaulknerKG, . Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from National Osteoporosis Risk Assessment. J Bone Miner Res2002;17:2222–30.
10.
HochbergMC, GreenspanS, WasnichRD, . Changes in bone density and turnover explain the reductions in incidence of nonverterbal fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab2002;87:1586–92.
11.
MarcusR, WongM, HunterHIII, StockJL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev2002;23:16–37.
12.
DelmasP, SeemanE.Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone2004;34:599–604.
13.
ChesnutCHIII, RoseCJ. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res2001;16:2163–72.
14.
RossPD, DavisJW, EpsteinRS, . Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med1991;114:919–23.
15.
NevittMC, RossPD, PalermoL, . The association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: the effect of number and spinal location of fractures. Bone1999;25:613–9.
16.
BouxseinML.Bone quality: where do we go from here?Osteoporosis Init; 2003;14(Suppl 5):S118–27.
17.
KleerekoperM, VillanuevaAR, StanciuJ, . The role of three-dimensional trabecular microstructure in the pathogenesis of vertebral compression fractures. Calcif Tissue Int1985;37:594–597.
18.
ParfittAM.Implications of architecture for the pathogenesis and prevention of vertebral fracture. Bone1992;13Suppl:S41–7.
19.
DemspterDW.The contribution of trabecular architecture to cancellous bone quality. J Bone Miner Res2000;15:20–3.
20.
GarneroP, HausherrE, ChapuyMC, . Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res1996;11:1531–8.
21.
WeinsteinRS.True strength. J Bone Miner Res2000;15:621–5.
22.
BoivinG, MeunierPJ.Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res2002;43:535–7.
23.
RubinCT, RubinJ.Biomechanics of Bone. In:FavusM, editor. Primer on the metabolic bone diseases and disorders of Mineral Metabolism, 4th edition. Philadelphia (PA): Lippincott, Williams & Wilkins; 1999. p. 40.
24.
AkkusO, Polyakova-AkkusA, AdarF, SchafflerMB.Aging and microstructural compartments in human compact bone. J Bone Miner Res2003;18:1012–9.
25.
CiarellaTE, FyhrieDP, ParfittAM.Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone2003;32:311–5.
26.
HiranoT, TurnerCH, ForwoodMR, . Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation?Bone2000;21:13–20.
27.
MashibaT, HiranoT, TurnerCH, . Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces biomechanical properties in dog rib. J Bone Miner Res2000;15:613–20.
28.
ChapuyMC, ArlotME, DuboeufF, . Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med1992;327:1637–42.
29.
ChapuyMC, ArlotME, DelmasPD, MeunierPJ.Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081–2.
30.
Dawson-HughesB, HarrisSS, KrallEA, DallalGE.Effect of calcium and vitamin D supplementation on bone density in elderly men and women 65 years of age or older. N Engl J Med2000;337:670–6.
31.
RoggiaC, GaoY, CenciS, . Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A2001;98:13960–5.
32.
ManolagasSC.Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev2000;21:115–37.
33.
TarantaA, BramaM, TetiA, . The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone2002;30:368–76.
34.
ManolagasSC, JilkaRL.Bone marrow, cytokines and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med1995;332:305–11.
35.
SavilleB, WormkeM, WangF, . Ligand-, cell- and estrogen receptor subtype (α/β)-dependent activation of GC-rich (Sp1) promoter elements. J Biol Chem2000;275:5379–87.
36.
PaechK, WebbP, KuiperGGJM, . Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science1997;277:1508–10.
37.
KousteniS, HanL, ChenJR, . Kinase-mediated regulation of common transcription factors accounts for bone-protective effects of sex steroids. J Clin Invest2003;111:1651–64.
38.
StepanJJ, AlenfeldF, BoivinG, . Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul2003;37:227–40.
39.
BoivinG, ChavassiuexP, MeunierP.Histomorphometry of bone. Effects of different treatments on bone remodeling and mineralization Osteogicky Bull2002;7:5–9.
40.
LindsayR, HartDM, ForrestC, BairdC.Prevention of postmenopausal osteoporosis in oophorectomized women. Lancet1980;2:1151–3.
41.
LufkinEG, WahnerHW, O'FallonWM, . Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med1992;117:1–9.
42.
Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA2002;288:321–33.
43.
Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;2911701–12.
44.
EttingerB, BlackDM, MitlakBH, . Reduction of vertebral fractures risk in postmenopausal women treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA2002;282:637–45.
45.
DelmasPD, EnsrudKE, AdachiJD, . Efficacy of raloxifene on vertebral fracture risk in postmenopausal women with osteoporosis: four year results from a randomized clinical trial. J Clin Endocrinol Metab2002;87:3609–17.
46.
ZaidiM, InzerilloAM, TroenB, . Molecular and clinical pharmacology of calcitonin. In:BilezikianJP, RaizL, RodanG, editors. Principles of bone biologySan Diego (CA): Academic Press; 2002:1423–40.
47.
SilvermanSL.Calcitonin. In:CummingsSR, CosmanF, JamalSA, editorsOsteoporosis: an evidence-based guide to prevention and management. Philadelphia (PA): American College of Physicians; 2002. p.197–208.
48.
ChestnutCIII,SilvermanSL, AdrianoK, . A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med2000;109:267–76.
49.
FleischH.Bisphosphonates: mechanisms of action. Endocr Rev1998;19:80–100.
50.
StaffordRS, DrielingRL, HershAL.National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch Intern Med2004;164:1525–30.
51.
DownsRWJr, BellNH, EttingerMP, . Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab2000;85:1783–8.
52.
SambrookPN, GeusensP, RibotC, . Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of Fosamax versus Evista comparison trial) International. J Intern Med2004;255:503–11.
53.
GarneroP, GineytsE, ArbaultP, . Different effects of bisphosphonate and estrogen therapy on the excretion of free and peptide-bound crosslinks. J Bone Miner Res1994;10:641–9.
54.
ChavassieuxPM, ArlotME, RedaC, . Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest1997;100:1475–80.
55.
EriksenEF, MelsenF, SodE, . Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone2002;31:620–5.
56.
LibermanUA, WeissSR, BrollJ, . Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med1995;333:1437–43.
57.
ToninoRP, MeunierPJ, EmkeyR, . Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab2000;85:3109–15.
58.
BlackDM, ThompsonDE, BauerDC, . Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab2000;85:4118–24.
59.
OrwollE, EttingerM, WeissS, . Alendronate for the treatment of osteoporosis in men. N Engl J Med2000;343:604–10.
60.
HarrisST, WattsNB, GenantHK, . Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA1999;282:1344–52.
61.
ReginsterJ, MinneHW, SorensenOH, . Randomized trial of the effects of risedronate on vertebral fractures in women with established osteoporosis. Vertebral efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int2000;11:83–91.
62.
McClungMR, GeusensP, MillerPD, . Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med2001;344:333–40.
63.
CohenS, LevyRM, KellerM, . Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel group study. Arthritis Rheum1999;42:2309–18.
64.
LiJ, MashibaT, BurrDB.Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int2001;69:281–6.
65.
MashibaT, TurnerCH, HiranoT, . Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone2001;28:524–31.
66.
SchafflerMB.Role of bone turnover in microdamage. Osteoporos Int2003;14Suppl 5:S73–80.
67.
WhyteMP, WenkertD, ClemensKL, . Bisphosphonate-induced osteopetrosis. N Engl J Med2003;349:457–63.
68.
RuggieroSL, MebrotraB, RosenbergTJ, EngroffSL.Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg2004;62:527–34.
69.
LindsayR, CosmanF, LoboRA, . Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab1999;84:3076–81.
70.
OttSM.Fractures after long-term alendronate therapy. J Clin Endocrinol Metab2001;86:1835.
71.
ToninoRP, SantoraA, RossPD.Safety of long-term alendronate. J Clin Endocrinol Metab2001;86:1835.
72.
BoneHG, HoskingD, DevogelaerJP, . Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med2004;350:1189–99.
73.
OdvinaCV, ZerwekhZE, RaoDS, . Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab2005;90:1294–301.
74.
McClungMR, San MartinJ, MillerPD, . Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med2005;165:1762–8.
75.
BauerE, AubJC, AlbrightF.Studies of calcium and phosphorus metabolism. V. A study of bone trabeculae as a readily available reserve supply of calcium. J Exp Med1929;49:145–61.
76.
NeerRM, ArnaudCD, ZanchettaJR, . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med2001;344:1434–41.
77.
LaneNE, SanchezS, ModinGW, . Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis. J Bone Miner Res2000;15:944–51.
78.
KurlandES, CosmanF, McMahonDJ, . Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab2000;85:3069–76.
79.
OrwollES, ScheeleWH, PaulS, . The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res2003;18:9–17.
80.
BodyJJ, GaichGA, ScheeleWH, . A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab2002;87:4528–35.
81.
DemspterDW, CosmanF, KurlandES, . Effects of daily treatment with parathyroid hormone on microarchitecture and bone turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res2001;16:1846–53.
82.
VahleJL, SatoM, LongGG.Skeletal changes in rats given daily subcutaneous injection of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol2002;30:312–21.
83.
LindsayR, ScheeleWH, NeerR, . Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med2004;164:2024–30.
84.
RiitmasterRS, BologneseM, EttingerMP, . Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab2000;85:2129–34.
85.
FrostHM.Coherence therapy of osteoporosis. Orthop Clin North Am1981;12:649–69.
Perez-CanoR, MorunoR, MontoyaMJ, . ADFR therapy in the prevention of bone loss after menopause. Clin Rheumatol1989;8(Suppl 2):56–60.
88.
SteinicheT, HaslingC, CharlesP, . The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: A randomized study comparing intermittent treatment and an ADFR regime. Bone1991;12:155–63.
89.
HodsmanAB, SteerBM, FraherLJ, DrostDJ.Bone densitometric and histomorphometric responses to sequential parathyroid (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner1991;14:67–83.
90.
FinkelsteinJ, HayesA, HunzelmanJ, . The effects of parathyroid hormone, alendronate or both in men with osteoporosis. N Engl J Med2003;349:1216–26.
91.
BlackD, GreenspanS, EnsrudK, . The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal women with osteoporosis. N Engl J Med2003;349:1207–15.
92.
MeunierPJ, RouxC, SeemanE, . The effects of strontium relanate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med2004;350:459–68.
93.
ChristoffersenJ, ChristoffersenMR, KolthoffN, BarenholdtO.Effects of strontium ions on growth and dissolution of hydroxyapatite and bone mineral detection. Bone1997;20:47–54.
94.
ReginsterJY, SeemanE, De VernejoulMC, . Strontium renalate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab2005;90:2816–22.
95.
BaggerYZ, TankoLB, AlexandersenP, . Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone2003;33:301–7.
96.
EnsrudKE, Barrett-ConnorEL, SchwartzA, . Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial Long-term Extension. J Bone Miner Res2004;19:1259–69.
97.
GallagherJC, RapuriPB, HaynatzkiG, DetterJR.Effect of discontinuation of estrogen, calcitriol, and combination of both on bone density and bone markers. J Clin Endocrinol Metab2002;87:4914–23.
98.
GreenspanSL, EmkeyRD, BoneHG, . Significant differential effects on alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med2002;137:875–83.
99.
OttS.Long-term safety of bisphosphonates. J Clin Endocrinol Metab2005;90:1897–9.
100.
BlackD, SchwartzA, EnsrudK, . A 5-year randomized trial of long-term efficacy and safety of alendonate: the FIT Long-term Extension (FLEX). J Bone Miner Res2004;19Suppl 1:117.
